| Lewis D Neace, DO | |
|
1012 South Third Street, Dayton, WA 99328 | |
| (509) 382-2531 | |
| (509) 382-3205 |
| Full Name | Lewis D Neace |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1012 South Third Street, Dayton, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184657876 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | OP00000734 (Washington) | Primary |
| 2083A0100X | Preventive Medicine - Aerospace Medicine | OP00000734 (Washington) | Secondary |
| Entity Name | Legacy Good Samaritan Hospital And Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780608216 PECOS PAC ID: 0547179939 Enrollment ID: O20031125000416 |
News Archive
Researchers report that they have found a potential molecular cause for the aggressive growth and spread of human head and neck squamous cell carcinoma, a highly malignant form of cancer with a very high death rate.
QRxPharma Limited and announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery.
Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra's drug discovery platform, Pharmacomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences ("NT Life"), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.
Most patients taking opioids for low back pain or other pain syndromes are prescribed low-to moderate doses, but a substantial number are given higher doses. Although there is no consensus on an absolute limit because tolerance varies over time among individual patients, what is known, however, is higher does are associated with elevated risks for side effects, addiction, overdoses and death.
Rhine-Waal students Aleksandar Hizman, Sabine Vollmer, Chantal Baumann, Kim Krieger and Lars Frohn, undergraduates in the Quality, Environment, Safety and Hygiene programme of the Faculty of Life Sciences, won first place in a research poster competition at the 10th annual European Detergents Conference, held in conjunction with the SEPAWA Congress in Fulda, Germany.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lewis D Neace, DO 1012 South Third Street, Dayton, WA 99328 Ph: (509) 382-2531 | Lewis D Neace, DO 1012 South Third Street, Dayton, WA 99328 Ph: (509) 382-2531 |
News Archive
Researchers report that they have found a potential molecular cause for the aggressive growth and spread of human head and neck squamous cell carcinoma, a highly malignant form of cancer with a very high death rate.
QRxPharma Limited and announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery.
Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra's drug discovery platform, Pharmacomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences ("NT Life"), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.
Most patients taking opioids for low back pain or other pain syndromes are prescribed low-to moderate doses, but a substantial number are given higher doses. Although there is no consensus on an absolute limit because tolerance varies over time among individual patients, what is known, however, is higher does are associated with elevated risks for side effects, addiction, overdoses and death.
Rhine-Waal students Aleksandar Hizman, Sabine Vollmer, Chantal Baumann, Kim Krieger and Lars Frohn, undergraduates in the Quality, Environment, Safety and Hygiene programme of the Faculty of Life Sciences, won first place in a research poster competition at the 10th annual European Detergents Conference, held in conjunction with the SEPAWA Congress in Fulda, Germany.
› Verified 8 days ago